Stanford University
Showing 171-180 of 500 Results
-
Rongting Huang
Postdoctoral Scholar, Pathology
BioDr. Huang is a computational biologist with academic interests in cancer genomics and spatial biology, particularly in the field of gynecologic cancers. During her Ph.D. under the mentorship of Dr. Yuanhua Huang, she developed statistical methods to detect allele-specific somatic copy number variations from single-cell and spatial transcriptomic data, aiming to understand genetic diversity in biological systems. Currently, her research focuses on advancing gynecologic cancer studies and women’s health through spatial technology platforms, computational modeling, and innovative data visualizations to uncover meaningful insights.
Outside of research, she enjoys hiking, rock climbing, and calligraphy, which help her stay creative and balanced. -
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Current Research and Scholarly InterestsDr. Jackson’s lab studies how primary cilia organize hormone, metabolite, and growth factor signaling in metabolic tissues and how their disruption causes obesity and diabetes. A second focus is defining the KRAS driven secreted factor networks that rewire the tumor microenvironment in lung and pancreatic cancers to promote immune evasion and therapeutic resistance. This work is revealing new secreted drug targets and combination strategies for precision oncology and metabolic disease.
-
Siddhartha Jaiswal
Associate Professor of Pathology
Current Research and Scholarly InterestsWe identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.
-
Olena Janczewski
Associate Director of Education, Pathology Ops Business Office
Current Role at StanfordAssociate Director of Education, Pathology
-
Kristin Jensen
Professor of Pathology
Current Research and Scholarly InterestsI am a clinical translational investigator with a primary interest in breast cancer biology, and the use of investigational and clinical ancillary techniques such as gene and tissue microarray analysis and immunohistochemistry in the diagnosis and prognosis of this disease. As a practicing cytopathologist, I also have an interest in improving the fine needle aspiration biopsy diagnosis of breast lesions, again using immunohistochemistry and gene expression analysis as adjuncts to cytomorphology.
-
Rathinaraja Jeyaraj
Postdoctoral Scholar, Pathology
BioI work at the intersection of AI, multimodal learning, and large-scale image analytics, with a strong focus on computational pathology and foundation models for healthcare. My current research interests include LLMs, VLMs, multimodal reasoning, whole-slide image analysis, retrieval-augmented generation (RAG), and trustworthy AI for medical decision support.
I develop scalable deep learning systems spanning WSI preprocessing, multiple instance learning, segmentation, survival prediction, and multimodal image-text modeling. My work also involves attention interpretability, contrastive learning, pathology foundation model adaptation, and large-scale AI pipelines. Beyond healthcare AI, I have experience in time-series forecasting, distributed computing, cloud infrastructure, and real-time computer vision systems for industrial and smart-city applications.
I am particularly interested in building reliable, interpretable, and clinically meaningful AI systems that bridge computer vision, multimodal learning, and large-scale reasoning. -
Jeyun Jo
Postdoctoral Scholar, Pathology
BioDr. Jeyun Jo received his Pharm.D. from Pusan National University in 2016 and his Ph.D. in pharmacy at the same institution in 2021. His thesis studies focused on the first total synthesis of anmindenol A and optimization of 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cells. He then worked for one year as a senior research scientist at Chong Kun Dang, a leading pharmaceutical company in Korea, where he developed large-sacale synthetic processes for engineered peptides. In May 2022, he joined the Bogyo lab at Stanford University as a postdoctoral fellow. His current research focuses on developing highly selective inhibitors and activity-based probes targeting specific serine hydrolases in pathogenic bacteria and cancer.
